The new APIC Guidance on Handling of Insoluble Matter and Foreign Particles in the Manufacture of Active Pharmaceutical Ingredients

The new APIC Guidance on Handling of Insoluble Matter and Foreign Particles in the Manufacture of Active Pharmaceutical Ingredients

The occurrence of foreign particles in the manufacture of active pharmaceutical ingredients is always undesirable. For the responsible QA departments it involves an increased effort as concerns the search for the root causes and for CAPA measures. A new APIC Guidance offers concrete recommendations for the GMP compliant handling of foreign particles in APIs, intermediates and raw materials.

Foreign particles in APIs or medicinal preparations are undesirable and sometimes lead to a recall of the batches concerned. Depending on the type of particles their presence in active pharmaceutical ingredients may be harmless; in many cases they are inevitable. In any case the manufacturer must find an adequate way how to handle those impurities visible to the human eye. The search for a guideline or another official document in the relevant regulations is in vain. Visible particles or fibres are only mentioned in the USP chapter <790>, in chapter 2.9.20 of the European Pharmacopoeia as well as in the United States Food, Drug and Cosmetic Act (FD&C Act).

In order to remedy this lack of guidance or recommendations a group of experts within APIC has drawn up a guidance on the handling of foreign particles. This “Guidance on Handling of insoluble Matter and Foreign Particles in APIs” describes in detail

  • the types of particles which can often occur during the manufacture of APIs, API intermediates and raw materials (including packaging materials),
  • suitable measures to minimize the presence of particles or to remove them,
  • how to determine them analytically
  • how to identify the source and to carry out subsequent CAPA measures and an adequate risk management.

This APIC guidance offers valuable assistance for all API manufacturers that are confronted with the problem of the occurrence of foreign particles in their products, intermediates or raw materials. The implementation of the very concrete and practicable recommendations in this guidance offers also valuable supporting arguments for GMP inspections or audits and can help to avoid unpleasant surprises.

http://www.gmp-compliance.org/enews_05022_The-new-APIC-Guidance-on-Handling-of-Insoluble-Matter-and-Foreign-Particles-in-the-Manufacture-of-Active-Pharmaceutical-Ingredients_9300,S-WKS_n.html

///////APIC Guidance,   Handling of Insoluble Matter and Foreign Particles, Manufacture, Active Pharmaceutical Ingredients

Finally published: new Annex 16 on QP Certification and Batch Release

Finally published: new Annex 16 on QP Certification and Batch Release

The European Commission finally has published the new EU-GMP Guideline Annex 16 “Certification by a Qualified Person and Batch Release“.

The European Commission has published the final version of the revised EU-GMP Guideline Annex 16 “Certification by a Qualified Person and Batch Release”. Deadline for coming into operation is 15 April 2016.

As one important topic, it has been pointed out that the major task of a Qualified Person (QP) is the certification of a batch for its release. In this context, the QP must personally ensure the responsibilities listed in chapter 1.6 are fulfilled.  In chapter 1.7 a lot of additional responsibilities are listed which need to be secured by the QP. The work can be delegated and the QP can rely on the respective Quality Management Systems. However “the QP should have on-going assurance that this reliance is well founded” (1.7). Amongst these twenty-one tasks are for example:

  • Starting materials comply and the supply chain is secured, including GMP assessments by third parties
  • The necessary audits have been performed and the audit reports are available
  • Manufacturing and testing performance are compliant with the MA
  • Manufacturing and testing processes are validated
  • Changes have been evaluated and investigations completed

It is important to mention in this context that “the ultimate responsibility for the performance of an authorised medicinal product over its lifetime; its safety, quality and efficacy lies with the marketing authorisation holder (MAH). However “the QP is responsible for ensuring that each individual batch has been manufactured and checked in compliance with laws in force (…), in accordance with the requirements of the marketing authorisation (MA) and with Good Manufacturing Practice (GMP)” (see General Principles).

In the case that the QP has to rely on the correct functioning of the quality management system of other sites, the QP “should ensure that a written final assessment and approval of third party audit reports has been made”. The QP should also “be aware of the outcome of an audit with critical impact on the product quality before certifying the relevant batches.”

Another important section clarifies the role of the QP when it comes to deviations, implementing main features of the EMA Position Paper on QP Discretion (which was issued in February 2006 and updated January 2008). Chapter 3 of the draft describes the “handling of unexpected deviations”. A batch with an unexpected deviation from details contained within the Marketing Authorisation and/or GMP may be certified if a risk assessment is performed, evaluating a “potential impact of the deviation on quality, safety or efficacy of the batch(es) concerned and conclusion that the impact is negligible.” Depending on the outcome of the investigation and the root cause, the submission of a variation to the MA for the continued manufacture of the product might be required.

During the consultation phase, stakeholders expressed their concerns regarding the sampling of imported products. Now the new annex is clear on this: “Samples may either be taken after arrival in the EU, or be taken at the manufacturing site in the third country in accordance with a technically justified approach which is documented within the company’s quality system. (…) Any samples taken outside the EU should be shipped under equivalent transport conditions as the batch that they represent.”

The new annex is rather short on other importation requirements. These requirements will probably be defined in the new Annex 21

http://www.gmp-compliance.org/enews_05058_Finally-published-new-Annex-16-on-QP-Certification-and-Batch-Release_9336,15099,15138,Z-QAMPP_n.html



.////////////published, new Annex 16, QP Certification and Batch Release